Dechra Launches Domidine Equine Sedative in the US Quick Takeaways: Why It Matters? Dechra’s US launch of Domidine (detomidine) adds a generic, cost‑effective alpha‑2 agonist to the equine sedation market, giving veterina...
Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways Why It Matters? CosACTHen gives Dechra a differentiated diagnostic anchor in canine endocrinology and should strengthen its existing Cushing’s/Addison’s franchise built around Vetoryl. As the first and only FDA‑approved cosyntropin spec...
Quick Takeaways: Why It Matters? Relocating the HQ to Boston embeds Dechra in a top-tier life sciences cluster, improving access to R&D talent, BD opportunities, and capital for innovation-driven growth. The shift also signals a stronger strategic emphasis on...
Quick Takeaways: Why It Matters? The VOHC seal gives Vetradent Dental Wipes strong clinical credibility, making vets more likely to recommend them as a trusted home-care option. By adding another VOHC-approved product, Dechra deepens its positionin...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
